Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine
Phase 2
Recruiting
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000026043
- Lead Sponsor
- Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
1) Previously received TAS-102 or regorafenib 2) Serious drug allergy (excluding oxaliplatin) 3) Serious myelosuppression 4) Active infectious disease 5) Interstitial lung disease or pulmonary fibrosis 6) Watery diarrhea 7) Serious comorbid illness (intestinal paralysis, obstruction, uncontrolled diabetes, renal failure, liver failure, etc) 8) Other active malignancies 9) Pregnancy, breast feeding, or women who desire to preserve fecundity. Men who want his partner to be pregnant 10) Patients who were judged inappropriate for the entry to this study by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate
- Secondary Outcome Measures
Name Time Method Progression free survival Overall survival frequency and grade of adverse events